Novo Nordisk Slashes Wegovy Price Amid FDA Compounding Crackdown to Boost Medication Accessibility
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
Novo Nordisk Slashes Wegovy Price Amid FDA Compounding Crackdown to Boost Medication Accessibility
-
Narrado por:
-
De:
Acerca de esta escucha
In this timely episode, we explore Novo Nordisk's strategic move to temporarily reduce Wegovy pricing to $199 for the first month and $499 thereafter for new self-paying patients. This price cut coincides with the FDA ending its grace period for compounded GLP-1 medications, potentially reshaping access to weight loss treatments. We discuss the implications for patients seeking affordable options, with remarkable success stories highlighting Wegovy's effectiveness—87% of users losing over 10% of their body weight. Plus, get exclusive insights on Novo Nordisk's upcoming oral Wegovy formulation that could revolutionize obesity treatment. Whether you're considering weight management options or following pharmaceutical industry trends, this episode delivers essential information on the changing landscape of GLP-1 medications and what it means for consumers and healthcare providers alike.
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones